Park Ha Biological Technology Prices $2 Million Registered Direct Offering

Park Ha Biological Technology Co., Ltd. disclosed the pricing of its registered direct offering. The offering raised $2 million from institutional investors. The Manila Times detailed the terms of the capital raise. Proceeds are intended to support the company’s research and development activities. The funding will aid expansion of its biotechnology product pipeline. The company plans to allocate resources toward clinical trials and manufacturing. Investors view the raise as a vote of confidence in Park Ha’s growth prospects. Future updates will reveal how the capital is deployed across projects.